GlycoMimetics Financials

GLYC Stock  USD 0.28  0.01  3.70%   
Based on the key indicators related to GlycoMimetics' liquidity, profitability, solvency, and operating efficiency, GlycoMimetics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At present, GlycoMimetics' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 6.1 B, whereas Other Liabilities is forecasted to decline to about 226 K. Key indicators impacting GlycoMimetics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.02280.0126
Way Up
Slightly volatile
Current Ratio1.821.9196
Notably Down
Pretty Stable
The financial analysis of GlycoMimetics is a critical element in measuring its lifeblood. Investors should not minimize GlycoMimetics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(39.77 Million)

  
Understanding current and past GlycoMimetics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of GlycoMimetics' financial statements are interrelated, with each one affecting the others. For example, an increase in GlycoMimetics' assets may result in an increase in income on the income statement.
Please note, the presentation of GlycoMimetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, GlycoMimetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of GlycoMimetics' management manipulating its earnings.

GlycoMimetics Stock Summary

GlycoMimetics competes with Mineralys Therapeutics,, Foghorn Therapeutics, Inventiva, Dyne Therapeutics, and Trevi Therapeutics. GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland. Glycomimetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 52 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS38000Q1022
CUSIP38000Q102
LocationMaryland; U.S.A
Business AddressPO Box 65,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.glycomimetics.com
Phone240 243 1201
CurrencyUSD - US Dollar

GlycoMimetics Key Financial Ratios

GlycoMimetics Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets142.8M94.3M51.8M45.3M11.1B11.6B
Other Current Liab9.4M8.7M7.0M5.2M5.7B6.0B
Net Debt(134.2M)(88.3M)(47.0M)(41.0M)(10.7M)(11.2M)
Retained Earnings(309.5M)(372.9M)(419.6M)(456.5M)(494.4B)(469.6B)
Accounts Payable2.1M2.1M970.2K868.1K329.3K312.8K
Cash137.0M90.3M47.9M41.8M10.7M10.2M
Other Assets(169.0)1.6M411.01.01.151.09
Other Current Assets1.2M532.5K2.7M1.8M371.3M370.3M
Total Liab14.6M12.7M8.9M6.9M5.8B6.1B
Total Current Assets138.3M90.3M50.7M43.8M11.1B11.6B
Common Stock49.0K52.3K54.4K64.4K64.5K37.7K
Net Tangible Assets154.2M128.2M81.6M42.9M49.4M46.9M
Net Receivables2.1K1.3K144.0K175.8K136.6K149.1K
Inventory(4.3B)(1.2B)(533.8M)(144.4K)(130.0K)(136.5K)
Net Invested Capital128.2M81.6M42.9M38.4M5.3M5.0M
Net Working Capital125.8M79.0M41.8M37.0M5.3M5.0M
Capital Stock49.0K52.3K54.4K64.4K64.5K58.3K
Short Term Debt898.5K1.0M918.6K741.6K66.9M70.3M

GlycoMimetics Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash(21.2M)(46.8M)(42.4M)(6.1M)(31.1B)(29.5B)
Free Cash Flow(39.3M)(57.5M)(46.5M)(34.9M)(31.1B)(29.6B)
Depreciation270.8K264.6K207.1K153.3K35.2M36.9M
Capital Expenditures68.5K14.9K84.2K21.4K10.0K9.5K
Net Income(51.0M)(63.4M)(46.7M)(36.9M)(37.9B)(36.0B)
End Period Cash Flow137.0M90.3M47.9M41.8M10.7B11.3B
Other Non Cash Items680.8K749.0K828.5K864.9K2.0B2.1B
Change To Netincome6.2M6.9M6.8M4.7M5.4M4.9M
Investments(68.5K)(14.9K)(84.2K)(20.6K)20.0K21.0K

GlycoMimetics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining GlycoMimetics's current stock value. Our valuation model uses many indicators to compare GlycoMimetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GlycoMimetics competition to find correlations between indicators driving GlycoMimetics's intrinsic value. More Info.
GlycoMimetics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, GlycoMimetics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GlycoMimetics' earnings, one of the primary drivers of an investment's value.

GlycoMimetics Systematic Risk

GlycoMimetics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. GlycoMimetics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on GlycoMimetics correlated with the market. If Beta is less than 0 GlycoMimetics generally moves in the opposite direction as compared to the market. If GlycoMimetics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one GlycoMimetics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of GlycoMimetics is generally in the same direction as the market. If Beta > 1 GlycoMimetics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in GlycoMimetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GlycoMimetics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of GlycoMimetics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0726

At present, GlycoMimetics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

GlycoMimetics March 19, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of GlycoMimetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of GlycoMimetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of GlycoMimetics based on widely used predictive technical indicators. In general, we focus on analyzing GlycoMimetics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build GlycoMimetics's daily price indicators and compare them against related drivers.

Complementary Tools for GlycoMimetics Stock analysis

When running GlycoMimetics' price analysis, check to measure GlycoMimetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlycoMimetics is operating at the current time. Most of GlycoMimetics' value examination focuses on studying past and present price action to predict the probability of GlycoMimetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlycoMimetics' price. Additionally, you may evaluate how the addition of GlycoMimetics to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Share Portfolio
Track or share privately all of your investments from the convenience of any device
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world